Natera (NASDAQ:NTRA) Price Target Raised to $220.00

Natera (NASDAQ:NTRA) had its price objective boosted by Wells Fargo & Company from $215.00 to $220.00 in a research note issued to investors on Friday morning, MarketBeat Ratings reports. Wells Fargo & Company currently has an equal weight rating on the medical research company’s stock.

NTRA has been the topic of a number of other research reports. Wall Street Zen raised shares of Natera from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. William Blair assumed coverage on shares of Natera in a research report on Tuesday, April 14th. They issued an “outperform” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Tuesday, April 21st. Morgan Stanley cut their price objective on shares of Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Finally, Robert W. Baird lifted their price objective on shares of Natera from $239.00 to $257.00 and gave the stock an “outperform” rating in a research report on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $256.00.

Natera Stock Performance

NASDAQ NTRA opened at $194.24 on Friday. The company has a market capitalization of $27.64 billion, a price-to-earnings ratio of -119.17 and a beta of 1.57. The company’s 50-day simple moving average is $202.23 and its two-hundred day simple moving average is $215.02. Natera has a one year low of $131.81 and a one year high of $256.36.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. The business had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative net margin of 9.05% and a negative return on equity of 15.72%. During the same quarter last year, the firm posted ($0.41) EPS. Equities analysts expect that Natera will post -1.71 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Solomon Moshkevich sold 3,405 shares of Natera stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $203.69, for a total value of $693,564.45. Following the completion of the sale, the insider directly owned 142,295 shares in the company, valued at $28,984,068.55. This trade represents a 2.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 3,070 shares of Natera stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $193.74, for a total transaction of $594,781.80. Following the completion of the sale, the chief financial officer owned 58,291 shares of the company’s stock, valued at $11,293,298.34. This trade represents a 5.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 38,266 shares of company stock worth $7,747,808 in the last quarter. 5.63% of the stock is currently owned by corporate insiders.

Institutional Trading of Natera

A number of institutional investors have recently bought and sold shares of the stock. Horizon Investments LLC boosted its stake in Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after purchasing an additional 44 shares in the last quarter. Sound Income Strategies LLC boosted its stake in Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after purchasing an additional 45 shares in the last quarter. Savvy Advisors Inc. boosted its stake in Natera by 3.1% in the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after purchasing an additional 46 shares in the last quarter. Parallel Advisors LLC boosted its stake in Natera by 5.5% in the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after purchasing an additional 47 shares in the last quarter. Finally, First Horizon Corp boosted its stake in Natera by 5.5% in the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after purchasing an additional 51 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: JPMorgan raised its price target on Natera to $265 from $260 and kept an overweight rating, signaling confidence in further upside from current levels. JPMorgan raises Natera price target
• Positive Sentiment: Wells Fargo also lifted its target to $220 from $215, indicating continued analyst support despite a more neutral equal-weight stance. Wells Fargo raises Natera price target
• Positive Sentiment: First-quarter revenue came in well above expectations at $696.6 million, up 38.8% year over year, and the company also reported gross margin of 64.7%, showing strong top-line growth. Natera Q1 results
• Neutral Sentiment: Natera updated full-year 2026 revenue guidance to $2.7 billion-$2.8 billion, roughly in line with consensus, which suggests the outlook is steady but not a major surprise. Natera guidance update
• Negative Sentiment: Profitability remains a concern: Natera posted a quarterly loss of $0.60 per share, wider than the expected $0.53 loss, despite the revenue beat. Natera earnings miss
• Negative Sentiment: Recent insider selling, including a CEO stock sale, may add pressure by reinforcing concerns about valuation after the stock’s strong run. Natera CEO stock sale

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.